408 related articles for article (PubMed ID: 27664392)
1. Systemic treatment and management approaches for medullary thyroid cancer.
Ernani V; Kumar M; Chen AY; Owonikoko TK
Cancer Treat Rev; 2016 Nov; 50():89-98. PubMed ID: 27664392
[TBL] [Abstract][Full Text] [Related]
2. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
[TBL] [Abstract][Full Text] [Related]
3. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
[No Abstract] [Full Text] [Related]
4. Medullary thyroid carcinoma - Adverse events during systemic treatment: risk-benefit ratio.
Maciel LMZ; Magalhães PKR
Arch Endocrinol Metab; 2017; 61(4):398-402. PubMed ID: 28658345
[TBL] [Abstract][Full Text] [Related]
5. Management of advanced medullary thyroid cancer.
Hadoux J; Pacini F; Tuttle RM; Schlumberger M
Lancet Diabetes Endocrinol; 2016 Jan; 4(1):64-71. PubMed ID: 26608066
[TBL] [Abstract][Full Text] [Related]
6. Genetics of medullary thyroid cancer: An overview.
Accardo G; Conzo G; Esposito D; Gambardella C; Mazzella M; Castaldo F; Di Donna C; Polistena A; Avenia N; Colantuoni V; Giugliano D; Pasquali D
Int J Surg; 2017 May; 41 Suppl 1():S2-S6. PubMed ID: 28506408
[TBL] [Abstract][Full Text] [Related]
7. Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both
Demir Gündoğan B; Sağcan F; Tuğ Bozdoğan S; Balcı Y; Tuncel Daloğlu F; Çağlar Çıtak E
J Clin Res Pediatr Endocrinol; 2021 Aug; 13(3):342-346. PubMed ID: 32702947
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer.
Hadoux J; Schlumberger M
Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):335-347. PubMed ID: 28911729
[TBL] [Abstract][Full Text] [Related]
9. [Cabozantinib: Mechanism of action, efficacy and indications].
Cochin V; Gross-Goupil M; Ravaud A; Godbert Y; Le Moulec S
Bull Cancer; 2017 May; 104(5):393-401. PubMed ID: 28477875
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional targeting of oncogene addiction in medullary thyroid cancer.
Valenciaga A; Saji M; Yu L; Zhang X; Bumrah C; Yilmaz AS; Knippler CM; Miles W; Giordano TJ; Cote GJ; Ringel MD
JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135308
[TBL] [Abstract][Full Text] [Related]
11. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment.
Dabelić N; Jukić T; Fröbe A
Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884
[TBL] [Abstract][Full Text] [Related]
12. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve
Wirth LJ; Brose MS; Elisei R; Capdevila J; Hoff AO; Hu MI; Tahara M; Robinson B; Gao M; Xia M; Maeda P; Sherman E
Future Oncol; 2022 Sep; 18(28):3143-3150. PubMed ID: 35969032
[TBL] [Abstract][Full Text] [Related]
13. Vandetanib therapy in medullary thyroid cancer.
Grabowski P; Briest F; Baum RP; Zaknun JJ; Kulkarni HR; Zeitz M; Hörsch D
Drugs Today (Barc); 2012 Nov; 48(11):723-33. PubMed ID: 23170308
[TBL] [Abstract][Full Text] [Related]
14. Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.
Subbiah V; Hu MI; Mansfield AS; Taylor MH; Schuler M; Zhu VW; Hadoux J; Curigliano G; Wirth L; Gainor JF; Alonso G; Adkins D; Godbert Y; Ahn MJ; Cassier PA; Cho BC; Lin CC; Zalutskaya A; Barata T; Trask P; Scalori A; Bordogna W; Heinzmann S; Brose MS
Thyroid; 2024 Jan; 34(1):26-40. PubMed ID: 38009200
[No Abstract] [Full Text] [Related]
15. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Wells SA; Gosnell JE; Gagel RF; Moley J; Pfister D; Sosa JA; Skinner M; Krebs A; Vasselli J; Schlumberger M
J Clin Oncol; 2010 Feb; 28(5):767-72. PubMed ID: 20065189
[TBL] [Abstract][Full Text] [Related]
16. Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives.
Ceolin L; Duval MADS; Benini AF; Ferreira CV; Maia AL
Endocr Relat Cancer; 2019 Aug; 26(9):R499-R518. PubMed ID: 31252403
[TBL] [Abstract][Full Text] [Related]
17. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.
Dadu R; Hu MN; Grubbs EG; Gagel RF
Recent Results Cancer Res; 2015; 204():227-49. PubMed ID: 26494392
[TBL] [Abstract][Full Text] [Related]
18. Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.
Krajewska J; Olczyk T; Jarzab B
Expert Rev Clin Pharmacol; 2016; 9(1):69-79. PubMed ID: 26536165
[TBL] [Abstract][Full Text] [Related]
19. Vandetanib and the management of advanced medullary thyroid cancer.
Campbell MJ; Seib CD; Gosnell J
Curr Opin Oncol; 2013 Jan; 25(1):39-43. PubMed ID: 23202050
[TBL] [Abstract][Full Text] [Related]
20. [Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas].
Chougnet CN; Schlumberger M; Leboulleux S; Baudin E
Bull Cancer; 2014 Sep; 101(9):891-5. PubMed ID: 25296193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
